<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=35476375865279447&ev=PageView&noscript=1"/>

Torrent Pharmaceuticals Limited

NSE: TORNTPHARM · Lot size: 250

Torrent Pharmaceuticals Limited Open Interest & PCR Analysis

4,163.8Updated 21 Apr 2026, 01:26 pm IST
PCR
0.69
Bearish signal
Max Pain
4,120
Spot above by ₹44
Total CE OI
653K
Call writers
Total PE OI
450K
Put writers
OI Buildup Signal
Neutral
Price movement < 0.3% threshold
Put-Call Ratio Gauge
0 — Bearish1.0 — Neutral2.0+ — Bullish

Data as of 2026-04-18

Frequently Asked Questions

What is Torrent Pharmaceuticals Limited PCR (Put-Call Ratio) today?
Torrent Pharmaceuticals Limited's current PCR is 0.69. A PCR above 1.2 is considered bullish (more put writing = floor support); below 0.8 is bearish; 0.8–1.2 is neutral. Torrent Pharmaceuticals Limited's PCR of 0.69 indicates bearish sentiment.
What is Torrent Pharmaceuticals Limited OI buildup type today?
Torrent Pharmaceuticals Limited is currently showing neutral positioning with no significant directional bias. This is determined by comparing today's price change direction with the direction of total OI change — using the standard F&O buildup classification framework.
What is total CE and PE open interest for Torrent Pharmaceuticals Limited?
Torrent Pharmaceuticals Limited has total CE (call) OI of 652750 contracts and total PE (put) OI of 450250 contracts for the nearest expiry. The PCR is 0.69.
How is open interest analysis useful for Torrent Pharmaceuticals Limited trading?
OI analysis for Torrent Pharmaceuticals Limited helps identify institutional positioning. High CE OI at a strike = call writers defending that level (resistance). High PE OI = put writers defending that level (support). The buildup type tells you whether smart money is building fresh positions (bullish/bearish) or exiting existing ones.
What is the max pain for Torrent Pharmaceuticals Limited?
Torrent Pharmaceuticals Limited's max pain is ₹4,120 — the strike price where option writers (sellers) collectively suffer the least financial loss at expiry. The current spot price vs max pain deviation guides near-term directional bias into expiry.